Abstract
Introduction: To address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument-Short Form (FCI-SF) (F-CAP®), called the eCDR and eFCI, respectively. Methods: The CDR and FCI-SF were adapted for remote, unsupervised, online use based on item response analysis of the standard instruments. Participants completed the eCDR and eFCI first in clinic, and then at home within 2 weeks. Results: Of the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU), 50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI, respectively, at home. Discussion: These results show initial feasibility in developing and administering online instruments to remotely assess and monitor cognitive decline along the CU to MCI/very mild dementia continuum. Validation is an important next step.
| Original language | English (US) |
|---|---|
| Article number | e12331 |
| Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2022 |
Keywords
- Alzheimer's disease
- Brain Health Registry
- aging research
- internet
- remote online instruments
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, No. 1, e12331, 2022.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form
AU - Howell, Taylor
AU - Gummadi, Shilpa
AU - Bui, Chau
AU - Santhakumar, Jessica
AU - Knight, Kristen
AU - Roberson, Erik D.
AU - Marson, Daniel
AU - Chambless, Carol
AU - Gersteneker, Adam
AU - Martin, Roy
AU - Kennedy, Richard
AU - Zhang, Yue
AU - Morris, John C.
AU - Moulder, Krista L.
AU - Mayo, Connie
AU - Carroll, Maria
AU - Li, Yan
AU - Petersen, Ronald C.
AU - Stricker, Nikki H.
AU - Nosheny, Rachel L.
AU - Mackin, Scott
AU - Weiner, Michael W.
N1 - Funding Information: Funding: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health (RF1AG059909). This project was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF‐CTSI Grant Number UL1 TR001872. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors gratefully acknowledge the following funding sources for the Brain Health Registry: National Institute on Aging, the Alzheimer's Association, California Department of Public Health, Patient Centered Research Outcomes Institute, Alzheimer's Drug Discovery Foundation, The Rosenberg Alzheimer's Project, the Ray and Dagmar Dolby Family Fund, Connie and Kevin Shanahan, General Electric, GHR, and The Drew Foundation. Additionally, the authors would like to acknowledge the Veterans Affairs and the Northern California Institute for Research and Education (NCIRE). The authors further appreciate the contributions of all eVAL participants and study partners, as well as all the individuals, including faculty and staff members, who contributed to the study planning and operations of the eVAL study. The ADRCs were instrumental in recruiting, evaluating, and following the participants being reported in this paper; the grants that support those ADRCs are as follows. For the Washington University Knight ADRC: P30 AG066444; P01 AG03991, and P01 AG026276. For the UAB ADRC: P20AG068024 and UL1TR003096. For the Mayo Clinic ADRC: P30 AG062677. Funding Information: Taylor Howell, Shilpa Gummadi, Chau Bui, Jessica Santhakumar, Kristen Knight, Carol Chambless, Adam Gersteneker, Roy Martin, Connie Mayo, Krista L. Moulder, Maria Carroll, and Yan Li have no interests to declare. Rachel L. Nosheny received support for her work from the NIH; received funding for academic travel from the Mild Cognitive Impairment (MCI) 2020 Symposium; and served on the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline (SCD) Professional Interest Area (PIA) “Dyadic Patterns of Subjective Report” workgroup. R. Scott Mackin has received research support from the National Institute of Mental Health and Johnson and Johnson. Nikki H. Stricker has received research support outside the scope of this work from the NIA, Alzheimer's Association, and Biogen; a Mayo Clinic invention disclosure has been submitted for remote cognitive assessment tools outside the scope of this work (the Stricker Learning Span and the Mayo Test Drive platform). Ronald C. Petersen receives funding from the National Institute on Aging: P30 AG062677, U01 AG006786, U01 AG024904, U24 AG057437 and National Institute for Neurological Disorders and Stroke: Uf1 NS125417. He consults for Roche, Inc., Merck, Inc, Biogen, Inc., Genentech, Inc., Eisai, Inc. and Nestle, Inc. He receives royalties from Oxford University Press and UpToDate. John C. Morris is funded by NIH grants # P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. Neither his nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Daniel Marson and UAB Research Foundation (UABRF) have previously received royalty income and other compensation for the use of the FCI‐SF in a clinical trial. He receives support from the NIH and is also the inventor of the FCI‐SF, which is owned by the UABRF. He and his company receive compensation for sales and services related to the FCI‐SF. He serves as a paid consultant to UCSD in connection to the e‐VAL research project and the present paper. Richard Kennedy and Yue Zhang receive support from NIH grants R01 AG057684 and R01AG059009. Erik D. Roberson receives support for his work from the following funding sources: NIH, Bluefield Project to Cure Frontotemporal Dementia, Alzheimer's Drug Discovery Foundation. He has also received support from the Alzheimer's Association, Alector, the Weston Brain Institute, and BrightFocus Foundation. He has served on advisory boards for Biogen, AGTC, and AVROBIO, and on a DSMB for Lilly. Michael W. Weiner receives support for his work from the following funding sources: NIH: 5U19AG024904‐14; 1R01AG053798‐01A1; R01 MH098062; U24 AG057437‐01; 1U2CA060426‐01; 1R01AG058676‐01A1; and 1RF1AG059009‐01, DOD: W81XWH‐15‐2‐0070; 0W81XWH‐12‐2‐0012; W81XWH‐14‐1‐0462; W81XWH‐13‐1‐0259, PCORI: PPRN‐1501‐26817, California Dept. of Public Health: 16–10054, U. Michigan: 18‐PAF01312, Siemens: 444951–54249, Biogen: 174552, Hillblom Foundation: 2015‐A‐011‐NET, Alzheimer's Association: BHR‐16‐459161; The State of California: 18–109929. He also receives support from Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI‐BHR), The Stroke Foundation, and the Veterans Administration. He has served on Advisory Boards for Eli Lilly, Cerecin/Accera, Roche, Alzheon, Inc., Merck Sharp & Dohme Corp., Nestle/Nestec, PCORI/PPRN, Dolby Family Ventures, National Institute on Aging (NIA), Brain Health Registry and ADNI. He serves on the Editorial Boards for Alzheimer's & Dementia, TMRI, and MRI. He has provided consulting and/or acted as a speaker/lecturer to Cerecin/Accera, Inc., Alzheimer's Drug Discovery Foundation (ADDF), Merck, BioClinica, Eli Lilly, Indiana University, Howard University, Nestle/Nestec, Roche, Genentech, NIH, Lynch Group GLC, Health & Wellness Partners, Bionest Partners, American Academy of Neurology (AAN), NYU, Japanese Government Alliance, National Center for Geriatrics and Gerontology (Japan), US Against Alzheimer's, Society for Nuclear Medicine and Molecular Imaging (SNMMI), The Buck Institute for Research on Aging, FUJIFILM‐Toyama Chemical (Japan), Garfield Weston, Baird Equity Capital, and T3D Therapeutics. He holds stock options with Alzheon, Inc., Alzeca, and Anven. The following entities have provided funding for academic travel; Kenes, Intl., Merck, ADCS, ATRI, Eli Lilly, The Alzheimer's Association, Merck, Tokyo University, Kyoto University, AAN, AC Immune, CHU Toulouse, St. George Hospital University, Indiana U., U. Melbourne, Australian Catholic University, Japanese Government Alliance, National Center for Geriatrics and Gerontology (Japan), US Against Alzheimer's, NYU, USC, and SNMMI. Funding Information: Funding: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health (RF1AG059909). This project was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors gratefully acknowledge the following funding sources for the Brain Health Registry: National Institute on Aging, the Alzheimer's Association, California Department of Public Health, Patient Centered Research Outcomes Institute, Alzheimer's Drug Discovery Foundation, The Rosenberg Alzheimer's Project, the Ray and Dagmar Dolby Family Fund, Connie and Kevin Shanahan, General Electric, GHR, and The Drew Foundation. Additionally, the authors would like to acknowledge the Veterans Affairs and the Northern California Institute for Research and Education (NCIRE). The authors further appreciate the contributions of all eVAL participants and study partners, as well as all the individuals, including faculty and staff members, who contributed to the study planning and operations of the eVAL study. The ADRCs were instrumental in recruiting, evaluating, and following the participants being reported in this paper; the grants that support those ADRCs are as follows. For the Washington University Knight ADRC: P30 AG066444; P01 AG03991, and P01 AG026276. For the UAB ADRC: P20AG068024 and UL1TR003096. For the Mayo Clinic ADRC: P30 AG062677. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: To address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument-Short Form (FCI-SF) (F-CAP®), called the eCDR and eFCI, respectively. Methods: The CDR and FCI-SF were adapted for remote, unsupervised, online use based on item response analysis of the standard instruments. Participants completed the eCDR and eFCI first in clinic, and then at home within 2 weeks. Results: Of the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU), 50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI, respectively, at home. Discussion: These results show initial feasibility in developing and administering online instruments to remotely assess and monitor cognitive decline along the CU to MCI/very mild dementia continuum. Validation is an important next step.
AB - Introduction: To address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument-Short Form (FCI-SF) (F-CAP®), called the eCDR and eFCI, respectively. Methods: The CDR and FCI-SF were adapted for remote, unsupervised, online use based on item response analysis of the standard instruments. Participants completed the eCDR and eFCI first in clinic, and then at home within 2 weeks. Results: Of the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU), 50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI, respectively, at home. Discussion: These results show initial feasibility in developing and administering online instruments to remotely assess and monitor cognitive decline along the CU to MCI/very mild dementia continuum. Validation is an important next step.
KW - Alzheimer's disease
KW - Brain Health Registry
KW - aging research
KW - internet
KW - remote online instruments
UR - http://www.scopus.com/inward/record.url?scp=85145035844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145035844&partnerID=8YFLogxK
U2 - 10.1002/dad2.12331
DO - 10.1002/dad2.12331
M3 - Article
AN - SCOPUS:85145035844
SN - 2352-8729
VL - 14
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12331
ER -